Opinion|Videos|March 21, 2025
Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations
Panelists discuss how the 5-year follow-up data from the CROWN trial support lorlatinib as a frontline treatment for ALK-positive non–small cell lung cancer NSCLC with brain metastasis. For frontline therapy, starting at full dose is preferred, adjusting if needed. Post progression, lorlatinib can be continued or combined with other agents. Biomarker testing for ROS1 is essential, with recent data (TRIDENT-1 trial) favoring lorlatinib for ROS1-positive central nervous system (CNS) involvement. Novel agents like taletrectinib and zidesamtinib from TRUST-I/II and ARROS-1 trials show promise in expanding treatment options for ROS1-positive NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the 5-year follow-up data from the CROWN trial and discuss how these findings inform your first-line treatment approach and in managing ALK-positive NSCLC with brain metastasis. (Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409.)
- Do you prefer starting patients at the full dose with subsequent dose reductions if necessary, or initiating at a lower dose and titrating upward as tolerated?
- For patients receiving lorlatinib in the frontline setting, how do you manage treatment following disease progression?
- Briefly discuss your approach to biomarker testing for ROS1 alterations and how recent data inform your treatment decisions in this space.
- How do the latest data from TRIDENT-1 trial inform your treatment approach for patients with ROS1 alterations and CNS involvement? (Drilon A, et al. NEJM. 2024;390:118-131.)
- Briefly comment on the TRUST-I/II (Perol, M et al. ESMO 2024. Abs 1289P) and ARROS-1 (Besse B, et al. ESMO 2024. Abs 1256MO) trials. Where do you see these novel agents (eg, taletrectinib and zidesamtinib) fitting in the treatment paradigm?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
5